You are here

Eisai

Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO

Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO

Fierce Pharma

Alzheimer's disease

Flag link:

Alzheimer's Association campaigns for broader Leqembi coverage: report

Alzheimer's Association campaigns for broader Leqembi coverage: report

Fierce Pharma

Alzheimer's disease

Flag link:

VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm

VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm

Endpoints

Alzheimer's disease

Flag link:

Eisai projects $7B in sales by 2030 for new Alzheimer's drug

Eisai projects $7B in sales by 2030 for new Alzheimer's drug

Endpoints

Alzheimer's disease

Flag link:

FDA sets July decision date for full approval of Leqembi

FDA sets July decision date for full approval of Leqembi

BioSpace

Alzheimer's disease

Flag link:

ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount

ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount

Fierce Pharma

Alzheimer's disease

Flag link:

Despite recent approvals, significant unmet need remains in Alzheimer’s market

Despite recent approvals, significant unmet need remains in Alzheimer’s market

Clinical Trials Arena

Alzheimer's disease

Avanir Pharmaceuticals

Flag link:

Medicare maintains limits on Eisai’s new Alzheimer’s drug

Medicare maintains limits on Eisai’s new Alzheimer’s drug

BioPharma Dive

Alzheimer's disease

Flag link:

Eisai Anticipates Full Approval of Leqembi as Early as July

Eisai Anticipates Full Approval of Leqembi as Early as July

BioSpace

Alzheimer's disease

Flag link:

BioSpace Layoff Tracker 2023: Grifols, Frequency, Eliem and More Cut Staff

BioSpace Layoff Tracker 2023: Grifols, Frequency, Eliem and More Cut Staff

BioSpace

Frequency Therapeutics

Eliem Therapeutics

Aligos Therapeutics

Thermo Fisher Scientific

Magenta Therapeutics

Y-mAbs Therapeutics

Century Therapeutics

Elevation Oncology

Calithera Biosciences

Editas Medicine

Flag link:

Eisai gives first glimpse into Alzheimer’s drug launch

Eisai gives first glimpse into Alzheimer’s drug launch

BioPharma Dive

Alzheimer's disease

Flag link:

With all eyes on new Alzheimer's med, Eisai lays off 91 staffers on its Fycompa team

With all eyes on new Alzheimer's med, Eisai lays off 91 staffers on its Fycompa team

Fierce Pharma

Flag link:

Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval

Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval

Motley Fool

Alzheimer's disease

Flag link:

Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?

Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?

Clinical Trials Arena

clinical trials

Alzheimer's disease

Flag link:

After FDA nod, Eisai and Biogen file lecanemab in EU

After FDA nod, Eisai and Biogen file lecanemab in EU

Pharmaphorum

Alzheimer's disease

Flag link:

Eisai learns from Biogen’s Aduhelm disaster

Eisai learns from Biogen’s Aduhelm disaster

EP Vantage

Alzheimer's disease

Flag link:

Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy

Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy

BioPharma Dive

Alzheimer's disease

Flag link:

FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision

FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision

BioPharma Dive

Alzheimer's disease

Flag link:

Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say

Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say

Stat

Alzheimer's disease

Flag link:

3rd patient death potentially tied to Eisai's Alzheimer's drug reported

3rd patient death potentially tied to Eisai's Alzheimer's drug reported

Fierce Biotech

Alzheimer's disease

clinical trials

Flag link:

Pages